描述（Description）
IL-21 protein is an immunomodulatory cytokine that promotes the transition from innate immunity to adaptive immunity. It induces B cells to produce IgG(1) and IgG(3), harnessing an effective antibody response to fight viral infections. GMP IL-21 Protein, Human is the recombinant human-derived IL-21 protein, expressed by E. coli , with tag free.
纯度（Purity）
≥95%, by SDS-PAGE (under reducing (R) & Non-reducing conditions, visualized by Coomassie staining)
氨基酸序列（Target Protein Sequence）
HKSSSQGQDRHMIRMRQLIDIVDQLKNYVNDLVPEFLPAPEDVETNCEWSAFSCFQKAQLKSANTGNNERIINVSIKKLKRKPPSTNAGRRQKHRLTCPSCDSYEKKPPKEFLERFKSLLQKMIHQHLSSRTHGSEDS
制剂（Trait）
Lyophilized from a 0.2 μm filtered solution of 20 mM PB, 150 mM NaCl, pH 7.0
复溶（Reconstitution）
It is recommended to redissolve in sterile deionized water.
保存条件&效期（Storage & Stability）
Stored at -20°C for 1 years. After reconstitution, it is stable at 4°C for 1 week or -20°C for longer (with carrier protein). It is recommended to freeze aliquots at -20°C or -80°C for extended storage.Please avoid repeated freeze-thaw cycles.
运输方式(Shipping)
In general, recombinant proteins are provided as lyophilized powder which are shipped at ambient temperature.
Bulk packages of recombinant proteins are provided as frozen liquid. They are shipped out with blue ice unless customers require otherwise.
生物活性（Bioactivity）
Measured by its ability to enhance IFN-gamma secretion in NK-92 human natural killer lymphoma cells. The ED50 for this effect is ≤ 20 ng/mL. The bioactivity of recombinant Human IL21 is higher than the other competing product.
电泳（SDS-PAGE）
Human Activin A Protein, Tag Free on SDS-PAGE under reducing (R) and non-reducing (NR) conditions. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95%.
特别提示：本公司的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用。
关键字： GMP级;高纯度;批间一致;生物活性;科研专供;
在生物科技领域，丰度蛋白专注重组蛋白供应，以“丰度的风帆为蛋白提供动力，丰度为蛋白护航”为使命，赋能生命科学发展。
苏州丰度依托先进技术平台，打造成熟生产体系，严控基因工程设计、细胞培养、蛋白纯化等环节，优化工艺与管理，确保产品高纯度、高活性且批间一致。产品覆盖基础研究、生物医药研发等多领域，为科研及生产提供多样、适配产品，助力突破技术难题 。